This invention relates to methods and devices for reconstructing the ventricle and for sensing infarcted septum and left ventricle wall during percutaneous left ventricle reconstruction, particularly where there is congestive heart failure.
This invention also relates generally to devices for sizing a ventricle and related methods for positioning the device. More particularly, the invention relates to sizing devices for reducing the ventricular volume to improve the heart's pumping action
Heart failure occurs when the pumping ability of the heart becomes impaired. The term congestive heart failure (CHF) refers to heart failure that is accompanied by congestion of body tissues. Heart failure may be caused by a variety of conditions, including acute myocardial infarction, hypertension, valvular heart disease, or degenerative conditions of the heart muscle known collectively as cardiomyopathies. Heart failure may exist as either systolic or diastolic (preserved ejection fraction) failure, and right-sided or sided failure. Systolic failure involves a decrease in cardiac contractility and ejection fraction. In systolic heart failure, the ejection fraction declines progressively with increasing degrees of myocardial dysfunction. With a decrease in ejection fraction, there is a resultant increase in diastolic volume, ventricular dilation, ventricular wall tension, and ventricular end-diastolic pressure.
In certain pathological conditions, the ventricles of the heart become ineffective in pumping the blood, causing a back-up of pressure in the vascular system behind the ventricle. The reduced effectiveness of the heart is usually due to an enlargement of the heart. Coronary artery disease causes approximately 60% of congestive heart failure. Acute myocardial infarction (AMI) due to obstruction of a coronary artery is a common initiating event that can lead ultimately to heart failure. A myocardial ischemia may, for example, cause a portion of a myocardium of the heart to lose its ability to contract. Prolonged ischemia can lead to infarction of a portion of the myocardium (heart muscle) wherein the heart muscle dies and become scar tissue. Once this tissue dies, it no longer as a muscle and cannot contribute to the pumping action of the heart. When the heart tissue is no longer pumping effectively, that portion of the myocardium is said to be hypokinetic, meaning that it is less contractile than the uncompromised myocardial tissue. As this situation worsens, the local area of compromised myocardium may in fact bulge out as the heart contracts, further decreasing the hearts ability to move blood forward. When local wall motion moves in this way it is said to be dyskinetic. The dyskinetic portion of the myocardium may stretch and eventually form an aneurysmic bulge.
One problem with a large dilated left ventricle is that there is a significant increase in wall tension and/or stress both during diastolic filling and during systolic contraction. In a normal heart, the adaptation of muscle hypertrophy (thickening) and ventricular dilatation maintain a fairly constant wall tension for systolic contraction. However, in a failing heart, the ongoing dilation is greater than the hypertrophy and the result is a rising wall tension requirement for systolic contraction. This is felt to be an ongoing insult to the muscle myocyte resulting in further muscle damage. In response, the heart tissue remodels to accommodate the chronically increased filling pressures, further increasing the work that the now-compromised myocardium must perform. This vicious cycle of cardiac failure results in the symptoms of congestive heart failure such as shortness of breath on exertion, edema in the periphery, nocturnal dypsnia (a characteristic shortness of breath that occurs at night after going to bed), weight gain, and fatigue, to name a few. The increase in wall stress also occurs during diastolic filling. The stress increase requires a larger amount of oxygen supply, which can result in exhaustion of the myocardium leading to a reduced cardiac output of the heart.
Heart failure (HF), the heart's inability to pump an adequate volume of blood to the tissues, is the only major cardiovascular condition that continues to increase in incidence in the United States. Approximate 5 million patients are currently diagnosed with HF in the United States. The American Heart Association estimates that between 400,000 and 700,000 new HF cases develop each year. This condition is responsible for an estimated 900,000 hospitalizations annually—more than any other medical condition among the elderly. Approximately 6.5 million hospital days each year are attributed to and related to HF and as many as one third of those patients are readmitted for treatment of symptom recurrence within 90 days. Thus, it is not surprising that the cost of providing advanced medical care for the millions of patients suffering from HF is extraordinarily high—now estimated at more than $38 billion annually.
In certain pathological conditions, the ventricles of the heart become ineffective in pumping the blood, causing a back-up of pressure in the vascular system behind the ventricle. The reduced effectiveness of the heart is usually due to an enlargement of the heart. Coronary artery disease causes approximately 60% of congestive heart failure. Acute myocardial infarction (AMI) due to obstruction of a coronary artery is a common initiating event that can lead ultimately to heart failure. A myocardial ischemia may, for example, cause a portion of a myocardium of the heart to lose its ability to contract. Prolonged ischemia can lead to infarction of a portion of the myocardium (heart muscle) wherein the heart muscle dies and become scar tissue. Once this tissue dies, it no longer functions as a muscle and cannot contribute to the pumping action of the heart. When the heart tissue is no longer pumping effectively, that portion of the myocardium is said to be hypokinetic, meaning that it is less contractile than the uncompromised myocardial tissue. As this situation worsens, the local area of compromised myocardium may in fact bulge out as the heart contracts, further decreasing the hearts ability to move blood forward. When local wall motion moves in this way it is said to be dyskinetic. The dyskinetic portion of the myocardium may stretch and eventually form an aneurysmic bulge.
One problem with a large dilated left ventricle is that there is a significant increase in wall tension and/or stress both during diastolic filling and during systolic contraction. In a normal heart, the adaptation of muscle hypertrophy (thickening) and ventricular dilatation maintain a fairly constant wall tension for systolic contraction. However, in a failing heart, the ongoing dilatation is greater than the hypertrophy and the result is a rising wall tension requirement for systolic contraction. This is felt to be an ongoing insult to the muscle myocyte resulting in further muscle damage. In response, the heart tissue remodels to accommodate the chronically increased filling pressures, further increasing the work that the now-compromised myocardium must perform. This vicious cycle of cardiac failure results in the symptoms of congestive heart failure such as shortness of breath on exertion, edema in the periphery, nocturnal dypsnia (a characteristic shortness of breath that occurs at night after going to bed), weight gain, and fatigue, to name a few. The increase in wall stress also occurs during diastolic filling. The stress increase requires a larger amount of oxygen supply, which can result in exhaustion of the myocardium leading to a reduced cardiac output of the heart.
Prior treatments for heart failure associated with such dilatation fall into three general categories. The first being pharmacological treatment, for example, diuretics and ACE inhibitors. The second being assist devices, for example, pumps. Finally, surgical treatments also have been experimented with, for example, Dor or Jatene procedure, or left ventricular reconstruction (LVR).
A surgical procedure for reconstruction of the left ventricle, developed by Dr. Vincent Dor, involves surgery via sternotomy by placing the patient on a heart-lung machine. In this operation, the scar tissue is excluded, and a patch is placed where the scar was excluded in order to sculpt the contour of the restored ventricle, and thus, reshape the heart. This results in more efficient contractile function, as the ejection fraction increases and forward output improves. The technique requires open chest surgery (sternotomy or thoracotomy), and is universally considered an invasive procedure. Understandably, the risk, extended recovery period, and discomfort of the sternal incision act as a deterrent to patients and their physicians despite the need to address the disease state for which the procedure is designed.
Hence, it will be beneficial to achieve the desired sizing and shaping of the heart without the highly invasive open chest procedure. A minimally invasive procedure, for example one that is done using a catheter that is inserted into the femoral vein or artery and that accesses the left ventricle, could be highly desirable. Such a procedure shall be able to identify and exclude the infracted tissue, in a way that is comparable to the identification of the infracted tissue is accomplished by simple visualization in an open procedure, and maintain or create the apex that is necessary to recreate the proper functioning of a CHF heart. A proper recreation of the apex of the heart is essential for maintaining effective cardiac contraction.
As mentioned above, the infracted tissue is easily identified during an open chest surgery by visualization. During a closed chest procedure where the heart is accessed using minimally invasive techniques, as contemplated here, it is not possible to visually differentiate the infracted tissue from viable or reversibly-ischemic myocardium. While MRI and nuclear-uptake studies can identify the presence of scar, these are currently not feasible intraoperatively.
Thus, there is a need for sensing infarcted myocardium in the septum from the right or left ventricle, along with a method or device to reduce the left ventricular volume while preserving the apex, and, then to appropriately realign the apex of the left ventricle and alter the geometry and decrease the wall tension in order to improve cardiac ejection fraction).
The present invention describes a method and device to achieve left ventricular volume reduction using minimally invasive surgical techniques by:
1. detecting the appropriate infarcted location in the heart; and
2. reducing left ventricle volume while preserving the apex by realigning the ventricular apex to treat patients with congestive heart failure.
A goal of the present invention is to provide a limited access method for treating congestive heart failure. This is achieved by a minimally invasive technique to reduce left ventricular volume while preserving the apex, and a way of sensing infarcted myocardium (septum and left ventricle wall) to appropriately reconfigure the geometry of the left ventricle and properly align the apex to provide the desired pumping capability of the heart. The present invention may be performed trans-atrially, trans-arterially, or trans-venously, as through femoral vein (percutaneously) with a catheter.
This invention relates to a device and method for treatment of congestive heart failure patients, and particularly to sizing device and method for reducing ventricular volume in patients suffering from congestive heart failure. The device and method may be performed thoracoscopically off-pump which is less expensive and less traumatic to the patient than an open-chest and open-heart surgical technique.
A left ventricular reconstruction typically comprises excluding the infracted tissue. To exclude the infracted tissue, it is important to first locate the tissue to be “excluded”. This invention describes a method for identifying infracted tissue while performing left ventricular reconstruction using minimally invasive procedures. Such sensing techniques may include (but are not limited to), (1) pacing (infracted tissue has minimum or no electrical conduction), (2) angiography, (3) echocardiography, and (4) tissue Doppler.
In yet another embodiment, this invention describes a method for performing minimally invasive left ventricular volume reduction in a congestive heart failure heart using a catheter by (a) accessing septum of the heart through the right ventricle; (b) identifying infracted tissue in the septum; (c) advancing the catheter through the infracted tissue of the septum; (d) identifying infracted tissue on the left ventricle wall; (e) bringing together the infracted tissue of the left ventricle and the septum, thereby minimizing the volume of the left ventricle; and (f) recreating an apex of the heart such that the procedure results in the desired geometric configuration and ejection fraction.
Once the boundaries of the scar have been defined using a sensing technique, achieving the clinical goal is dependent on realignment of the apical spatial relationships, and a decrease in the size of the left ventricle to improve ejection fraction and stroke volume. In the process, this invention will diminish wall tension, and therefore oxygen consumption, as well as solving potential alignment disparities by repositioning the apex to an appropriate anatomical configuration.
Another embodiment of this invention comprises a catheter-based, minimally invasive procedure of introducing a catheter into the right ventricle of the heart, via the septum, and into the left ventricle to reduce the volume of the left ventricle while preserving the apex of the left ventricle. This method comprises performing minimally invasive left ventricular volume reduction in a congestive heart failure heart using a catheter by (a) accessing septum of the heart through the right ventricle; (b) identifying tissue in the septum; (c) advancing the catheter through the infarcted tissue of the septum; (d) identifying infracted tissue on the left ventricular wall; and (e) bringing the infracted tissue of the left ventricle and the septum closer to each other and thereby minimizing the volume of the left ventricle.
Another aspect of the present invention pertains to suturing device, and related suturing methods, for thoracoscopy device placement on the heart. The sutures of the present inventions may be placed thoracoscopically. The inventive techniques and devices are thus minimally invasive and less risky to patients.
The present invention has other advantages and features which will be more readily apparent from the following detailed description of the invention and the appended claims, when taken in conjunction with the accompanying drawings, in which:
Upon identifying this infarcted tissue, the physician threads the catheter 18 into the left ventricle 14 by advancing a perforating member 30 via a puncture through the tissue so identified in the septum 16. Perforating member 30 may be coextensive with catheter 18 or be fed through catheter 18. Advancing perforating member 30 can also be accomplished by using a retractable pointed element that is disposed at the distal tip of catheter 18. Alternatively, the catheter could be advanced over a steerable, sharp member that separately perforates the infarcted tissue of the septum. Once catheter 18 is in the left ventricle 14, the sensing element 20 is again used to confirm the location of additional infarcted tissue 23 in the left ventricular wall 24. Upon locating the infarcted tissue on the left ventricular wall, the physician advances the perforating member 30 through the tissue so identified until perforating member 30 is external to the ventricle and visible through the epicardium. The perforating member 30 shall then either be fixed on the surface of the heart with a disc or similar fixation member 32, or used to pull or retract additional fixation members or another grasping device, such as a suture (not shown), back through the free wall to the epicardium to the endocardium. Fixation member 32 is typically part of the catheter that is activated by maneuvering or activating something on the catheter
In the former case, perforating member 30, affixed via fixation member 32 to left ventricle wall 15 is withdrawn through the free ventricular wall, back through the dilated left ventricle chamber 14 and back through the septum 16 at the site of the original perforation. As the perforating element 30 is further withdrawn, it will reduce the position of the free wall until that wall becomes contiguous with the septum 16 (or nearly so). Thus, the short axis of the left ventricle 14 is diminished by the extent to which the septum and free LV wall are apposed.
The catheters used for the percutaneous LVR in accordance with the present invention may be steerable/maneuverable catheters as are commonly used in surgical procedures. Suturing devices used in the alternative iterations could be commonly used sutures such as Prolene™, or could be made of shape memory alloys, such as Nitinol™.
The above steps could be accomplished using the following steps and devices:
1. Continuous direct and non-invasive visualization of the process using endoscopy, echocardiography, or other known non-invasive methods.
2. Multiple (assuming one will not be adequate to accomplish the restoration) perforating elements with multiple epicardial “discs” or other dispersing or fixation members, which are pulled together simultaneously to reduce the volume of the left ventricle.
3. A counter, externally compressive maneuver to ensure even reduction of the ventricle with balance movement of each of the multiple discs and evagination of the intervening scar as the reduction is carried out.
4. Fixation of the penetrating members on the right side if the interventricular septum to cement the reduction. Expanding discs, slats, or other fixation members to distribute the forces over a large area will be used.
5. The bulk of the device, not the portions of the penetrating members between the free wall discs and the RV septal discs, will be removed from the vascular system. As such, only a remnant, or detachable portion of the members that traversed the septum, LV, and free wall will remain, fixed at both ends with elements that distribute tension over a substantial area to ensure durability. These detachable elements will be a short segment, since the perforated portion will have been shortened as the walls are brought in closer approximation.
6. Alternatively, the leading edge of the fixation member shall have a retention element, such that the leading edge of the fixation member is retained on the epicardium. Once the leading edge is in place, the catheter is retracted through the puncture that was previously made through the infarcted septum. The retraction of the catheter now leaves the fixation member bridging the wall of the left ventricle and the septum. The trailing edge of the fixation member shall also have a retention element such that the trailing edge of the retention element is on the septum facing the right ventricle. The objective here is to bring together the infarcted tissues of the septum and the left ventricular wall together such that the left ventricular volume is reduced to an appropriate size and shape for a congestive heart failure patient to recover the desired ejection fraction of the heart. With the leading and trailing edge retention devices on the epicardium and the septum, respectively, pulling them away from each other would bring the two walls together and thus result in a reduced volume of the left ventricle. The two walls could also be brought together using suturing devices that are well known in the art.
The procedure according to one embodiment of the present invention is shown in
In another embodiment, the procedure utilizes a thoracoscopic surgical approach, i.e., synching the infarcted tissue from the epicardial side as opposed to the endocardial approach described under the percutaneous procedure.
Delivery catheter 18, which may also could act as a sensing catheter (such as 30 in
The proximal and distal fixation elements 32a, 32b could also be made of two sub-elements as shown in
While there has been shown and described what is considered to be preferred embodiments of the invention, it will, of course, be understood that various modifications and changes in form or detail could readily be made without departing from the spirit of the invention. It is therefore intended that the invention be not limited to the exact forms described and illustrated, but should be constructed to cover all modifications that may fall within the scope of the appended claims.
This application is a divisional of U.S. patent Ser. No. 15/387,464 filed Dec. 21, 2016, now U.S. Pat. No. 10,398,557, which is a continuation of U.S. patent application Ser. No. 14/839,500 filed Aug. 28, 2015, now U.S. Pat. No. 9,526,618, which is a continuation of U.S. patent application Ser. No. 13/898,179 filed May 20, 2013, now U.S. Pat. No. 9,119,720, which is a continuation of U.S. patent application Ser. No. 11/961,990 filed Dec. 20, 2007, now U.S. Pat. No. 8,449,442, which is a continuation of U.S. patent application Ser. No. 11/248,521 filed on Oct. 12, 2005, which claims the benefit of under 35 U.S.C. § 109(e) of U.S. Provisional Patent Application No. 60/618,835, filed on Oct. 13, 2004, the full disclosures of which are incorporated herein by reference.
Number | Name | Date | Kind |
---|---|---|---|
4007743 | Blake | Feb 1977 | A |
5154709 | Johnson | Oct 1992 | A |
5295958 | Shturman | Mar 1994 | A |
5336252 | Cohen | Aug 1994 | A |
5482037 | Borghi | Jan 1996 | A |
5755697 | Jones et al. | May 1998 | A |
5810884 | Kim | Sep 1998 | A |
5830224 | Cohn et al. | Nov 1998 | A |
5865730 | Fox et al. | Feb 1999 | A |
5868770 | Rygaard | Feb 1999 | A |
5961440 | Schweich, Jr. et al. | Oct 1999 | A |
6010476 | Saadat | Jan 2000 | A |
6045497 | Schweich et al. | Apr 2000 | A |
6050936 | Schweich, Jr. et al. | Apr 2000 | A |
6059715 | Schweich, Jr. et al. | May 2000 | A |
6059719 | Yamamoto | May 2000 | A |
6080182 | Shaw et al. | Jun 2000 | A |
6125852 | Stevens et al. | Oct 2000 | A |
6155968 | Wilk | Dec 2000 | A |
6162168 | Schweich, Jr. et al. | Dec 2000 | A |
6165119 | Schweich, Jr. et al. | Dec 2000 | A |
6165120 | Schweich, Jr. et al. | Dec 2000 | A |
6166684 | Yoshikawa et al. | Dec 2000 | A |
6258021 | Wilk | Jul 2001 | B1 |
6260552 | Mortier et al. | Jul 2001 | B1 |
6406420 | McCarthy et al. | Jun 2002 | B1 |
6478029 | Boyd et al. | Nov 2002 | B1 |
6494211 | Boyd et al. | Dec 2002 | B1 |
6494825 | Talpade | Dec 2002 | B1 |
6511416 | Green et al. | Jan 2003 | B1 |
6572529 | Wilk | Jun 2003 | B2 |
6616684 | Vidlund et al. | Sep 2003 | B1 |
6623508 | Shaw et al. | Sep 2003 | B2 |
6705988 | Spence et al. | Mar 2004 | B2 |
6709382 | Horner | Mar 2004 | B1 |
6723038 | Schroeder et al. | Apr 2004 | B1 |
6746471 | Mortier et al. | Jun 2004 | B2 |
6776754 | Wilk | Aug 2004 | B1 |
6808488 | Mortier | Oct 2004 | B2 |
6859662 | Bombardini | Feb 2005 | B2 |
6890295 | Michels et al. | May 2005 | B2 |
7060021 | Wilk | Jun 2006 | B1 |
7146225 | Guenst et al. | Dec 2006 | B2 |
7326177 | Williamson | Feb 2008 | B2 |
7373207 | Lattouf | May 2008 | B2 |
7390329 | Westra et al. | Jun 2008 | B2 |
7431691 | Wilk | Oct 2008 | B1 |
7507200 | Okada | Mar 2009 | B2 |
7637924 | Gifford et al. | Dec 2009 | B2 |
7722523 | Mortier et al. | May 2010 | B2 |
7753923 | St. Goar et al. | Jul 2010 | B2 |
7766816 | Chin et al. | Aug 2010 | B2 |
7785248 | Annest et al. | Aug 2010 | B2 |
7842015 | Chachques | Nov 2010 | B2 |
7942854 | Von Oepen et al. | May 2011 | B1 |
8066766 | To et al. | Nov 2011 | B2 |
8123668 | Annest et al. | Feb 2012 | B2 |
8268009 | Teitelbaum et al. | Sep 2012 | B2 |
8394008 | Annest et al. | Mar 2013 | B2 |
8425402 | Annest et al. | Apr 2013 | B2 |
8449442 | Annest et al. | May 2013 | B2 |
8491455 | Annest et al. | Jul 2013 | B2 |
8506474 | Chin et al. | Aug 2013 | B2 |
8636639 | Annest et al. | Jan 2014 | B2 |
8968175 | Annest et al. | Mar 2015 | B2 |
8979750 | Bladel et al. | Mar 2015 | B2 |
8986189 | Chin et al. | Mar 2015 | B2 |
9039594 | Annest et al. | May 2015 | B2 |
9044231 | Annest et al. | Jun 2015 | B2 |
9095363 | Bladel et al. | Aug 2015 | B2 |
9119720 | Chin et al. | Sep 2015 | B2 |
9173711 | Butler et al. | Nov 2015 | B2 |
9173712 | Annest et al. | Nov 2015 | B2 |
9211115 | Annest et al. | Dec 2015 | B2 |
9259319 | Chin et al. | Feb 2016 | B2 |
9402722 | Annest et al. | Aug 2016 | B2 |
9486206 | Annest et al. | Nov 2016 | B2 |
9526618 | Chin et al. | Dec 2016 | B2 |
20010025171 | Mortier et al. | Sep 2001 | A1 |
20010041821 | Wilk | Nov 2001 | A1 |
20020058855 | Schweich, Jr | May 2002 | A1 |
20020077524 | Schweich, Jr. et al. | Jun 2002 | A1 |
20020077655 | Frova | Jun 2002 | A1 |
20020120298 | Kramer et al. | Aug 2002 | A1 |
20020123768 | Gilkerson et al. | Sep 2002 | A1 |
20020169359 | McCarthy et al. | Nov 2002 | A1 |
20020169360 | Taylor et al. | Nov 2002 | A1 |
20020188170 | Santamore et al. | Dec 2002 | A1 |
20020198563 | Gainor et al. | Dec 2002 | A1 |
20030032979 | Mortier et al. | Feb 2003 | A1 |
20030163165 | Bornzin et al. | Aug 2003 | A1 |
20030166992 | Schweich, Jr. et al. | Sep 2003 | A1 |
20030181928 | Vidlund et al. | Sep 2003 | A1 |
20030181951 | Cates | Sep 2003 | A1 |
20030220587 | Swenson | Nov 2003 | A1 |
20030233022 | Vidlund et al. | Dec 2003 | A1 |
20040064143 | Hicken et al. | Apr 2004 | A1 |
20040082837 | Willis | Apr 2004 | A1 |
20040088035 | Guenst et al. | May 2004 | A1 |
20040138526 | Guenst | Jul 2004 | A1 |
20040158123 | Jayaraman | Aug 2004 | A1 |
20040167374 | Schweich | Aug 2004 | A1 |
20040167580 | Mann et al. | Aug 2004 | A1 |
20040225304 | Vidlund et al. | Nov 2004 | A1 |
20040267306 | Blaeser et al. | Dec 2004 | A1 |
20050015109 | Lichtenstein | Jan 2005 | A1 |
20050065506 | Phan | Mar 2005 | A1 |
20050075723 | Schroeder et al. | Apr 2005 | A1 |
20050096498 | Houser et al. | May 2005 | A1 |
20050137688 | Salahieh et al. | Jun 2005 | A1 |
20050143620 | Mortier et al. | Jun 2005 | A1 |
20050149115 | Roue et al. | Jul 2005 | A1 |
20050192599 | Demarais | Sep 2005 | A1 |
20050215851 | Kim et al. | Sep 2005 | A1 |
20050288613 | Heil | Dec 2005 | A1 |
20060004408 | Morris et al. | Jan 2006 | A1 |
20060079736 | Chin et al. | Apr 2006 | A1 |
20060135962 | Kick et al. | Jun 2006 | A1 |
20060131238 | Hall | Jul 2006 | A1 |
20060161040 | McCarthy et al. | Jul 2006 | A1 |
20060161238 | Hall | Jul 2006 | A1 |
20060167416 | Mathis et al. | Jul 2006 | A1 |
20060178550 | Jenson | Aug 2006 | A1 |
20060200002 | Guenst | Sep 2006 | A1 |
20060241340 | Schroeder et al. | Oct 2006 | A1 |
20060247672 | Vidlund et al. | Nov 2006 | A1 |
20060276684 | Speziali | Dec 2006 | A1 |
20070005018 | Tkebuchava | Jan 2007 | A1 |
20070010876 | Salahieh et al. | Jan 2007 | A1 |
20070049971 | Chin et al. | Mar 2007 | A1 |
20070055303 | Vidlund et al. | Mar 2007 | A1 |
20070073274 | Chin et al. | Mar 2007 | A1 |
20070112244 | McCarthy et al. | May 2007 | A1 |
20070161846 | Nikotic et al. | Jul 2007 | A1 |
20070203503 | Salahieh et al. | Aug 2007 | A1 |
20070265658 | Nelson et al. | Nov 2007 | A1 |
20070287884 | Schena | Dec 2007 | A1 |
20080058650 | Saadat et al. | Mar 2008 | A1 |
20080082132 | Annest et al. | Apr 2008 | A1 |
20080097148 | Chin et al. | Apr 2008 | A1 |
20080234717 | Bruszewski | Sep 2008 | A1 |
20080269551 | Annest et al. | Oct 2008 | A1 |
20080294251 | Annest et al. | Nov 2008 | A1 |
20090093670 | Annest et al. | Apr 2009 | A1 |
20090270980 | Schroeder et al. | Oct 2009 | A1 |
20090287165 | Drapeau et al. | Nov 2009 | A1 |
20090287304 | Dahlgren et al. | Nov 2009 | A1 |
20100010538 | Juravic et al. | Jan 2010 | A1 |
20100016655 | Annest et al. | Jan 2010 | A1 |
20100030142 | Onishi | Feb 2010 | A1 |
20100057000 | Melsheimer et al. | Mar 2010 | A1 |
20100268020 | Chin et al. | Oct 2010 | A1 |
20110160750 | Annest et al. | Jun 2011 | A1 |
20110270191 | Paul et al. | Nov 2011 | A1 |
20110301622 | Oren | Dec 2011 | A1 |
20120190958 | Annest et al. | Jul 2012 | A1 |
20130090523 | Van Bladel et al. | Apr 2013 | A1 |
20130090672 | Butler et al. | Apr 2013 | A1 |
20130090684 | Van Bladel et al. | Apr 2013 | A1 |
20130096579 | Annest et al. | Apr 2013 | A1 |
20130324787 | Chin et al. | Dec 2013 | A1 |
20130325041 | Annest et al. | Dec 2013 | A1 |
20140031613 | Annest et al. | Jan 2014 | A1 |
20140051916 | Chin et al. | Feb 2014 | A1 |
20140330296 | Annest et al. | Nov 2014 | A1 |
20140350417 | Bladel et al. | Nov 2014 | A1 |
20150066082 | Moshe et al. | Mar 2015 | A1 |
20150066139 | Bladel et al. | Mar 2015 | A1 |
20150238182 | Annest et al. | Aug 2015 | A1 |
20160022422 | Annest et al. | Jan 2016 | A1 |
20160030026 | Bladel et al. | Feb 2016 | A1 |
20160089132 | Butler et al. | Mar 2016 | A1 |
20160095600 | Annest et al. | Apr 2016 | A1 |
20160120648 | Chin et al. | May 2016 | A1 |
20160206427 | Annest et al. | Jul 2016 | A1 |
20160262891 | Chin et al. | Sep 2016 | A1 |
20160338835 | Bladel et al. | Nov 2016 | A1 |
Number | Date | Country |
---|---|---|
1 078 644 | Feb 2001 | EP |
0006028 | Feb 2000 | WO |
200230335 | Apr 2002 | WO |
2003032818 | Apr 2003 | WO |
2004-043267 | May 2004 | WO |
2005092203 | Oct 2005 | WO |
2006044467 | Apr 2006 | WO |
2007022519 | Feb 2007 | WO |
2007-100409 | Sep 2007 | WO |
2013-049761 | Apr 2013 | WO |
Entry |
---|
European Examination Report of EP Patent Application 05810316.9 dated Mar. 10, 2009, 6 pages. |
Extended European Examination Report of EP Patent Application 06802038.7 dated Nov. 12, 2013, 13 pages. |
Office Action of EP Patent Application 06802038.7 dated Sep. 11, 2014, 4 pages. |
International Report on Patentability of PCT/US2012/058074 dated Apr. 10, 2014, 8 pages. |
International Report on Patentability of PCT/US2012/058176 dated Apr. 10, 2014, 11 pages. |
International Search Report and Written Opinion of PCT Application No. PCT/US06/22594, dated Oct. 1, 2008, 4 pages. |
International Search Report and Written Opinion of PCT Application No. PCT/US06/32663, dated Jul. 31, 2007, 5 pages. |
International Search Report and Written Opinion of PCT Application No. PCT/US08/64255, dated Sep. 29, 2008, 13 pages. |
International Search Report and Written Opinion of PCT Application No. PCT/US08/78810, dated Feb. 12, 2009, 9 pages. |
International Search Report and Written Opinion of PCT Application No. PCT/US09/51288, dated Sep. 15, 2009, 7 pages. |
International Search Report and Written Opinion of PCT Application No. PCT/US12/58074, dated Mar. 13, 2013, 18 pages. |
International Search Report and Written Opinion of PCT Application No. PCT/US2005/036690, dated Jul. 9, 2007, 6 pages. |
International Search Report and Written Opinion of PCT/US2012/058106, dated Nov. 26, 2012, 14 pages. |
International Search Report and Written Opinion of PCT/US2012/58176, dated Jan. 8, 2013, 19 pages. |
International Search Report and Written Opinion of PCT/US2012/058182, dated Mar. 1, 2013, 12 pages. |
USPTO—STIC Search Results—NPL (Dec. 11, 2014). |
USPTO—STIC Search Results—Patents (Dec. 11, 2014). |
International Search Report and Written Opinion of PCT Application No. PCT/US2014/053209 dated Mar. 2, 2015, 18 pages. |
International Search Report and Written Opinion of PCT Application No. PCT/US2014/038834 dated Oct. 16, 2014, 16 pages. |
International Report on Patentability of PCT Application No. PCT/US2014/038834 dated Dec. 3, 2015,11 pages. |
European Examination Report of EP Patent Application 12837466.7 dated Jun. 6, 2016, 14 pages. |
Number | Date | Country | |
---|---|---|---|
20190350711 A1 | Nov 2019 | US |
Number | Date | Country | |
---|---|---|---|
60618835 | Oct 2004 | US |
Number | Date | Country | |
---|---|---|---|
Parent | 15387464 | Dec 2016 | US |
Child | 16531810 | US |
Number | Date | Country | |
---|---|---|---|
Parent | 14839500 | Aug 2015 | US |
Child | 15387464 | US | |
Parent | 13898179 | May 2013 | US |
Child | 14839500 | US | |
Parent | 11961990 | Dec 2007 | US |
Child | 13898179 | US | |
Parent | 11248521 | Oct 2005 | US |
Child | 11961990 | US |